No Significant Weight Change With Adjuvant Sulfonylureas

This article originally appeared here.
Share this content:
No Significant Weight Change With Adjuvant Sulfonylureas
No Significant Weight Change With Adjuvant Sulfonylureas

WEDNESDAY, June 8, 2016 (HealthDay News) -- Sulfonylureas used as add-on therapy to metformin can maintain glycemic control in type 2 diabetes, without changing body weight, according to a study published online June 6 in Diabetes, Obesity and Metabolism.

Dennis Schrijnders, from the Diabetes Center in Zwolle, Netherlands, and colleagues conducted a prospective observational cohort study involving patients with type 2 diabetes, aged 18 years and older. Participants had received metformin as monotherapy for at least one year before receiving dual therapy by the addition of a sulfonylurea for one year or more. During five years of follow-up, the within-drug yearly change in body weight after receiving add-on therapy with individual sulfonylureas was assessed. Data were included for 2,958 patients.

The researchers observed no significant weight changes within and between any of the individual sulfonylureas after intensification of treatment (P = 0.24). No significant difference in weight was seen between the add-on therapy combinations (P = 0.26). The year before intensification, the average glycated hemoglobin was 7.2 percent, and dropped to below 7.0 percent the year after intensification.

"In patients with type 2 diabetes treated in primary care, strict glycemic control can be maintained with sulfonylureas used as add-on therapy to metformin, without the offset of relevant weight changes," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: Alzheimer's Mortality Up 55 Percent From 1999 to 2014

CDC: Alzheimer's Mortality Up 55 Percent From 1999 ...

More patients also dying at home, with the caregiving burden often falling on loved ones

Targeting ANGPTL3 Can Significantly Lower Cholesterol

Targeting <i>ANGPTL3</i> Can Significantly Lower Cholesterol

Two trials show promise for non-statin approach to cardiovascular disease prevention

Factors Raise Risk of Pregnancy-Related Stroke in Preeclampsia

Factors Raise Risk of Pregnancy-Related Stroke in Preeclampsia

Infections, clotting disorders, chronic hypertension all found to increase risk

is free, fast, and customized just for you!

Already a member?

Sign In Now »